한글목차

류마티스 관절염(RA)은 2023년 16개국에서 1,300만 명 이상의 환자가 진단될 것으로 예상되며, 현재 19개의 주요 RA 치료제가 시판되고 있습니다. 혁신 제품과 바이오시밀러를 포함해 등록 전 단계에 있는 의약품은 13개 품목이 있습니다.

지난 10년간 RA 임상시험을 주도한 영리 스폰서는 AbbVie(61건), Pfizer(48건), Boehringer Ingelheim(46건)이 그 뒤를 이었습니다.

아시아태평양과 북미에서 제휴가 가장 많았고, 유럽에서 인수가 가장 많았습니다. 남미와 아프리카에서는 라이선스 계약이 가장 많습니다.

이 보고서는 세계 류마티스 관절염(RA) 시장에 대해 조사했으며, 질환 개요와 함께 임상시험 동향, 파이프라인 개요, 향후 전망 등의 정보를 제공합니다.

목차

제1장 서문

제2장 주요 조사 결과

제3장 질병 상황

• 질병 개요
• 역학 개요
• 치료 개요

제4장 출시 약제 평가

• 주요 출시 약제
• 작용기서별 개요
• 투여 경로별 개요
• 출시 약제 프로파일과 판매량 예측

제5장 약가 설정과 상환 평가

• 연간 치료비
• 약가 설정과 상환 기간

제6장 파이프라인 약제 평가

• 제III상 파이프라인 약제
• 개발 단계별 개요
• 분자 유형별 개요
• 작용기서별 개요
• 투여 경로별 개요
• 의약품 특이적 상전이 성공률(PTSR)과 승인 가능성(LoA)
• 치료 분야 및 적응증 고유의 PTSR 및 LoA

제7장 임상시험 평가

• 과거 개요
• 상별 개요
• 상황별 개요
• 진행중 및 계획중인 시험의 상별 개요
• 가상 컴포넌트를 사용한 임상시험
• 지역적 개요
• 지역별 단일국 및 다국적 시험
• 상위 20개 스폰서와 상별 내역
• 상위 20개 스폰서의 상황별 내역
• 엔드포인트 상황별 개요
• 인종 및 민족별 개요
• 등록 데이터
• 임상시험 사이트 상위 20개국
• 세계의 상위 20개 사이트
• 실현 가능성 분석 - 지역적 개요
• 실현 가능성 분석 - 벤치마크 모델

제8장 거래 상황

제9장 상업적 평가

• 주요 시장 진출 기업

제10장 향후 시장 촉매

제11장 부록

영문목차

Abstract

This reports provides a data-driven overview of the current and future competitive landscape in RA therapeutics.

• More than 13 million diagnosed prevalent cases of RA are anticipated in 2023 in the 16 countries covered in GlobalData's epidemiology forecast for RA.
• There are 19 leading marketed drugs for the treatment of RA.
• There are 13 drugs in pre-registration stage, including innovator products and biosimilars.
• Commercial sponsors have led the clinical trials space for RA over the past 10 years, with AbbVie sponsoring the highest number of trials overall (61 trials), followed by Pfizer (48 trials) and Boehringer Ingelheim (46 trials).
• In the Asia-Pacific and North America regions, partnership was the most common type of deal, while acquisition was the most common type of deal in Europe. In South America and in Africa, the most common type of deal was licensing agreements.

Scope

GlobalData's RA: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Route of Administration
• Product Profiles with Sales Forecast
• Pricing and Reimbursement Assessment
• Annual Therapy Cost
• Time to Pricing and Time to Reimbursement
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the RA market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global RA market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

Table of Contents

1 Preface

• 1.1 Contents
• 1.2 Report Scope
• 1.3 List of Tables and Figures
• 1.4 Abbreviations

2 Key Findings

3 Disease Landscape

• 3.1 Disease Overview
• 3.2 Epidemiology Overview
• 3.3 Treatment Overview

4 Marketed Drugs Assessment

• 4.1 Leading Marketed Drugs
• 4.2 Overview by Mechanism of Action
• 4.3 Overview by Route of Administration
• 4.4 Marketed Drugs Profiles and Sales Forecasts

5 Pricing and Reimbursement Assessment

• 5.1 Annual Therapy Cost
• 5.2 Time to Pricing and Reimbursement

6 Pipeline Drugs Assessment

• 6.1 Phase III Pipeline Drugs
• 6.2 Overview by Development Stage
• 6.3 Overview by Molecule Type
• 6.4 Overview by Mechanism of Action
• 6.5 Overview by Route of Administration
• 6.6 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)
• 6.7 Therapy Area and Indication-specific PTSR and LoA

7 Clinical Trials Assessment

• 7.1 Historical Overview
• 7.2 Overview by Phase
• 7.3 Overview by Status
• 7.4 Overview by Phase for Ongoing and Planned Trials
• 7.5 Trials with Virtual Components
• 7.6 Geographic Overview
• 7.7 Single-Country and Multinational Trials by Region
• 7.8 Top 20 Sponsors with Breakdown by Phase
• 7.9 Top 20 Sponsors with Breakdown by Status
• 7.10 Overview by Endpoint Status
• 7.11 Overview by Race and Ethnicity
• 7.12 Enrollment Data
• 7.13 Top 20 countries for Trial Sites
• 7.14 Top 20 Sites Globally
• 7.15 Feasibility Analysis - Geographic Overview
• 7.16 Feasibility Analysis - Benchmark Models

8 Deals Landscape

• 8.1 Mergers, Acquisitions, and Strategic Alliances by Region
• 8.2 Recent Mergers, Acquisitions, and Strategic Alliances

9 Commercial Assessment

• 9.1 Key Market Players

10 Future Market Catalysts

11 Appendix

• 11.1 Methodology
• 11.2 Methodology - Sales Forecast
• 11.3 Methodology - Pricing and Reimbursement
• 11.4 Methodology - PTSR and LoA Analysis
• 11.5 About the Authors
• 11.6 Contact Us
• 11.7 Disclaimer